PDCD1 and non-small cell lung carcinoma: A similar meta-analysis in NSCLC, urothelial cancer and HNSCC showed that smokers benefited from anti PD-1/PD-L1 mono or combination therapy while nonsmokers benefitted from a combination of chemo- and immunotherapy [122].